Company: DNLI
Filing Date: 2025-04-17
Form Type: DEF 14A
Source: 0001714899-25-000087
Chunk: 50

Company: Denali Therapeutics Inc.
Filing Date: 2025-04-17
Form: DEF 14A
Chunk 50
---
 on the diversity and difficulty of these goals, in structuring the funding expectations at the beginning of the year, the Company believed that achievement of 70% of these challenging goals would be difficult, requiring focused effort and diligence, and would represent strong alignment with the Company’s business objectives that would make bonus pool funding at 100% levels appropriate.

Each goal is measured individually, and the percent of goals achieved determines the bonus payout, subject to the compensation committee's discretion to alter bonus funding and payouts:

| % of Goals Achieved |     | 25% |     | 40% |     | 50% |     | 60% |     | 70%  |     | 80%  |     | 90%  |     | 100% and/or Major value driver 
 (e.g. Phase 3, Drug Approval)  |
| % Pool Funding      |     | 0%  |     | 25% |     | 50% |     | 75% |     | 100% |     | 125% |     | 150% |     | 200%                           |

In January 2025, the compensation committee of our board of directors reviewed the progress against the applicable 2024 goals. In 2024 we met 5 out of 6 (83%) high-impact objective goals and 15 out of 17 (88%) of our other objective goals. As a result of these achievements, the compensation committee funded the bonus pool at 140% of target levels. The resulting bonuses to NEOs were as follows:

| Executive                 |     | 2024 Base Salary |         |     | Annual Target Bonus (% of base) |    |   |     | Funding Percentage |     |   |     | 2024 Earned Award |         |
|:--------------------------|:----|:-----------------|--------:|:----|:--------------------------------|---:|:--|:----|:-------------------|----:|:--|:----|:------------------|--------:|
| Ryan J. Watts, Ph.D.      |     | $                | 690,000 |     |                                 | 65 | % |     |                    | 140 | % |     | $                 | 627,969 |
| Alexander O. Schuth, M.D. |     | $                | 536,000 |     |                                 | 45 | % |     |                    | 140 | % |